Efficacy, Safety and Tolerability of Multiple Doses of Valsartan in Children With Hypertension With or Without CKD

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (493 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-01-24. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: kidneychronicckdtransplantationpressure
  Phrases that lowered it: patientsevaluatetherapychildrenupper
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 13.1% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 296 (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Blinding: triple (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports with a death: 11.9% (lowers risk) · Drug's FDA history
• Phase: 3 (lowers risk) · Design
• Minimum age: 1 (lowers risk) · Who can join
• Sponsor's past trials: 452 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 79.1% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports before start: 41149 (lowers risk) · Drug's FDA history
• Maximum age: 5 (raises risk) · Who can join
• Number of arms: 3 (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety and Tolerability of Valsartan in Children 6 to 17 Years of Age NCT01365481 · started 2011 · scored riskier than 30% of active trials completed
• Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age NCT01150357 · started 2010 · scored riskier than 50% of active trials completed
• Pharmacokinetics Following Single-dose of Valsartan in Japanese Pediatric Patients NCT01447485 · started 2011 · scored riskier than 9% of active trials completed
• Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension NCT01001572 · started 2009 · scored riskier than 16% of active trials completed
• An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension NCT02235909 · started 2015 · scored riskier than 58% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.